Spotlight on peginterferon-α-2a (40KD) in chronic hepatitis C

BioDrugs

Volumn 16, Issue 3, 2002, Pages 213-217

  Perry, Caroline M ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; PEGINTERFERON ALPHA2A; RIBAVIRIN; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ALOPECIA; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MYALGIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RIGOR; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 0036022693     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216030-00006     Document Type: Review

References (25)

1. Therapy of hepatitis C: Overview
2. Major therapeutic uses of interferons
3. Hepatitis C virus resistance to antiviral therapy
4. The interferons. Mechanism of action and clinical applications
5. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects
6. + T helper 1 responses during and after treatment
7. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a
8. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2A and may explain its enhanced efficacy in chronic hepatitis C (CHC)
9. Development of pegylated interferons for the treatment of chronic hepatitis C
10. The pharmacokinetic behavior of pegylated (40KDA) interferon alfa-2a (Pegasys™) in chronic hepatitis C patients after multiple dosing
11. Clearance of pegylated (40KDA) interferon alfa-2a (Pegasys™) is primarily hepatic
12. Pegylated (40KDA) interferon alfa-2a (Pegasys™) is unaffected by renal impairment
13. The pharmacokinetics of pegylated-40K interferon alfa-2A in chronic hepatitis C patients with cirrhosis
14. Drug interactions between PEG(40)K-IFNα-2a (PEGASYS) and cytochrome P450 (CYP450)-metabolized drugs are unlikely except for those metabolized by CYPIA2
15. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C
16. Peginterferon alfa-2a in patients with chronic hepatitis C
17. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
18. Evaluation of the safety and efficacy of once-weekly PEG interferon alfa-2a (PEGASYS™) for chronic hepatitis C. A multinational, randomized study
19. Pegylated (40kda) interferon alfa-2a (Pegasys™) is superior to interferon alfa-2a (Roferon-A®) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584
20. Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (PEGASYS™) and thrice weekly interferon alfa-2a (Roferon™) in patients with chronic hepatitis C and compensated cirrhosis
21. Therapy with pegylated (40KDA) interferon alfa-2a (Pegasys™) significantly enhances quality of life compared with standard interferon alfa-2a (Roferon-A®) in patients with chronic hepatitis C
22. The effect of successful anti-viral therapy on health-related quality of life for patients with chronic hepatitis C and cirrhosis
23. Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS®) compared with standard interferon alfa-2a
24. Improved work productivity, safety and quality of life with pegylated (40KDA) interferon alfa-2a (Pegasys™) therapy in the treatment of chronic hepatitis C
25. Therapy with Pegasys® demonstrates similar efficacy and significantly improved tolerability, quality of life and work productivity compared with Rebetron™ in patients with chronic hepatitis C